WISP-1/CCN4 regulates osteogenesis by enhancing BMP-2 activity

Journal of Bone and Mineral Research

Volumn 26, Issue 1, 2011, Pages 193-208

  Ono, Mitsuaki ^a   Inkson, Colette A ^a   Kilts, Tina M ^a   Young, Marian F ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

BMP; CCN; CYTOKINES; GROWTH FACTORS; OSTEOPROGENITORS; WISP1

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CCN PROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; WNT INDUCED SECRETED PROTEIN 1;

ADENOVIRUS; ANIMAL CELL; ARTICLE; BONE CELL; BONE DENSITY; BONE DEVELOPMENT; BONE MARROW CELL; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LENTIVIRINAE; LENTIVIRUS INFECTION; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PILOT STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STROMA CELL; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE;

ANIMALS; BONE AND BONES; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; ONCOGENE PROTEINS; OSTEOBLASTS; OSTEOGENESIS; PHENOTYPE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RECEPTORS, VITRONECTIN;

EID: 78650936271     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.205     Document Type: Article

References (79)

1. Parisi MS, Gazzerro E, Rydziel S, Canalis E., Expression and regulation of CCN genes in murine osteoblasts. Bone. 2006; 38: 671-677.
2. French DM, Kaul RJ, D'Souza AL, et al. WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol. 2004; 165: 855-867.
3. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ., WISP1 is a Wnt-1- and β-catenin-responsive oncogene. Genes Dev. 2000; 14: 585-595.
4. Hoeppner LH, Secreto FJ, Westendorf JJ., Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009; 13: 485-496.
5. Ling L, Nurcombe V, Cool SM., Wnt signaling controls the fate of mesenchymal stem cells. Gene. 2009; 433: 1-7.
6. Patel MS, Karsenty G., Regulation of bone formation and vision by LRP5. N Engl J Med. 2002; 346: 1572-1574.
7. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002; 346: 1513-1521.
8. Balemans W, Van Hul W., The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology. 2007; 148: 2622-2629.
9. Blom AB, Brockbank SM, van Lent PL, et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. Arthritis Rheum. 2009; 60: 501-512.
10. Geyer M, Grassel S, Straub RH, et al. Differential transcriptome analysis of intraarticular lesional vs intact cartilage reveals new candidate genes in osteoarthritis pathophysiology. Osteoarthritis Cartilage. 2009; 17: 328-335.
11. Inkson CA, Ono M, Kuznetsov SA, Fisher LW, Robey PG, Young MF., TGF-beta1 and WISP-1/CCN-4 can regulate each other's activity to cooperatively control osteoblast function. J Cell Biochem. 2008; 104: 1865-1878.
12. Katsube K, Sakamoto K, Tamamura Y, Yamaguchi A., Role of CCN, a vertebrate specific gene family, in development. Dev Growth Differ. 2009; 51: 55-67.
13. Brigstock DR., The CCN family: a new stimulus package. J Endocrinol. 2003; 178: 169-175.
14. Smerdel-Ramoya A, Zanotti S, Deregowski V, Canalis E., Connective tissue growth factor enhances osteoblastogenesis in vitro. J Biol Chem. 2008; 283: 22690-22699.
15. Smerdel-Ramoya A, Zanotti S, Stadmeyer L, Durant D, Canalis E., Skeletal overexpression of connective tissue growth factor impairs bone formation and causes osteopenia. Endocrinology. 2008; 149: 4374-4381.
16. Rydziel S, Stadmeyer L, Zanotti S, Durant D, Smerdel-Ramoya A, Canalis E., Nephroblastoma overexpressed (Nov) inhibits osteoblastogenesis and causes osteopenia. J Biol Chem. 2007; 282: 19762-19772.
17. Heath E, Tahri D, Andermarcher E, Schofield P, Fleming S, Boulter CA., Abnormal skeletal and cardiac development, cardiomyopathy, muscle atrophy and cataracts in mice with a targeted disruption of the Nov (Ccn3) gene. BMC Dev Biol. 2008; 8: 18.
18. Ivkovic S, Yoon BS, Popoff SN, et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development. 2003; 130: 2779-2791.
19. Arnott JA, Zhang X, Sanjay A, et al. Molecular requirements for induction of CTGF expression by TGF-beta1 in primary osteoblasts. Bone. 2008; 42: 871-885.
20. Konigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest. 2009; 119: 772-787.
21. Shimo T, Kubota S, Yoshioka N, et al. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res. 2006; 21: 1045-1059.
22. Kleer CG, Zhang Y, Merajver SD., CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs. 2007; 185: 95-99.
23. Bennewith KL, Huang X, Ham CM, et al. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 2009; 69: 775-784.
24. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR., Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005; 65: 8887-8895.
25. Maillard M, Cadot B, Ball RY, et al. Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol. 2001; 54: 275-280.
26. Tanaka S, Sugimachi K, Saeki H, et al. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene. 2001; 20: 5525-5532.
27. Kidd M, Modlin IM, Eick GN, Camp RL, Mane SM., Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. Am J Physiol Gastrointest Liver Physiol. 2007; 292: G191-200.
28. Kawaki H, Kubota S, Suzuki A, et al. Functional requirement of CCN2 for intramembranous bone formation in embryonic mice. Biochem Biophys Res Commun. 2008; 366: 450-456.
29. Kubota S, Takigawa M., CCN family proteins and angiogenesis: from embryo to adulthood. Angiogenesis. 2007; 10: 1-11.
30. Colston JT, de la Rosa SD, Koehler M, et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. Am J Physiol Heart Circ Physiol. 2007; 293: H1839-1846.
31. Leu SJ, Lam SC, Lau LF., Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem. 2002; 277: 46248-46255.
32. Lin CG, Leu SJ, Chen N, et al. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem. 2003; 278: 24200-24208.
33. Lin CG, Chen CC, Leu SJ, Grzeszkiewicz TM, Lau LF., Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J Biol Chem. 2005; 280: 8229-8237.
34. Vallacchi V, Daniotti M, Ratti F, et al. CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res. 2008; 68: 715-723.
35. Crockett JC, Schutze N, Tosh D, et al. The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5. Endocrinology. 2007; 148: 5761-5768.
36. Hoshijima M, Hattori T, Inoue M, et al. CT domain of CCN2/CTGF directly interacts with fibronectin and enhances cell adhesion of chondrocytes through integrin alpha5beta1. FEBS Lett. 2006; 580: 1376-1382.
37. Benini S, Perbal B, Zambelli D, et al. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene. 2005; 24: 4349-4361.
38. Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res. 2004; 64: 1987-1996.
39. Abreu JG, Ketpura NI, Reversade B, De Robertis EM., Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol. 2002; 4: 599-604.
40. Nakamura Y, Weidinger G, Liang JO, et al. The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling. J Clin Invest. 2007; 117: 3075-3086.
41. Maeda A, Nishida T, Aoyama E, et al. CCN family 2/connective tissue growth factor modulates BMP signalling as a signal conductor, which action regulates the proliferation and differentiation of chondrocytes. J Biochem. 2009; 145: 207-216.
42. Canalis E, Economides AN, Gazzerro E., Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev. 2003; 24: 218-235.
43. Abe E., Function of BMPs and BMP antagonists in adult bone. Ann N Y Acad Sci. 2006; 1068: 41-53.
44. Bishop GB, Einhorn TA., Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int Orthop. 2007; 31: 721-727.
45. Bi Y, Stuelten CH, Kilts T, et al. Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J Biol Chem. 2005; 280: 30481-30489.
46. Zilberberg L, ten Dijke P, Sakai LY, Rifkin DB., A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC Cell Biol. 2007; 8: 41.
47. Su F, Overholtzer M, Besser D, Levine AJ., WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev. 2002; 16: 46-57.
48. Zhao M, Zhao Z, Koh JT, Jin T, Franceschi RT., Combinatorial gene therapy for bone regeneration: cooperative interactions between adenovirus vectors expressing bone morphogenetic proteins 2, 4 and 7. J Cell Biochem. 2005; 95: 1-16.
49. Inkson CA, Ono M, Bi Y, Kuznetsov SA, Fisher LW, Young MF., The potential functional interaction of biglycan and WISP-1 in controlling differentiation and proliferation of osteogenic cells. Cells Tissues Organs. 2009; 189: 153-157.
50. Sommer B, Kuznetsov SA, Robey PG, O'Connell B, Cristiano RJ, Young MF., Efficient gene transfer into normal human skeletal cells using recombinant adenovirus and conjugated adenovirus-DNA complexes. Calcif Tissue Int. 1999; 64: 45-49.
51. Lin J, Patel SR, Cheng X, et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med. 2005; 11: 387-393.
52. Dean DB, Watson JT, Moed BR, Zhang Z., Role of bone morphogenetic proteins and their antagonists in healing of bone fracture. Front Biosci. 2009; 14: 2878-2888.
53. Chen D, Zhao M, Mundy GR., Bone morphogenetic proteins. Growth Factors. 2004; 22: 233-241.
54. Owen TA, Aronow M, Shalhoub V, et al. Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol. 1990; 143: 420-430.
55. Oka M, Kubota S, Kondo S, et al. Gene expression and distribution of connective tissue growth factor (CCN2/CTGF) during secondary ossification center formation. J Histochem Cytochem. 2007; 55: 1245-1255.
56. Minamizato T, Sakamoto K, Liu T, et al. CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways. Biochem Biophys Res Commun. 2007; 354: 567-573.
57. Pi L, Ding X, Jorgensen M, et al. Connective tissue growth factor with a novel fibronectin binding site promotes cell adhesion and migration during rat oval cell activation. Hepatology. 2008; 47: 996-1004.
58. Tan TW, Lai CH, Huang CY, et al. CTGF enhances migration and MMP-13 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Biochem. 2009; 107: 345-356.
59. Tan TW, Yang WH, Lin YT, et al. Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells. Carcinogenesis. 2009; 30: 258-268.
60. Gao R, Brigstock DR., A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells. Gut. 2006; 55: 856-862.
61. Yoshida Y, Togi K, Matsumae H, et al. CCN1 protects cardiac myocytes from oxidative stress via beta1 integrin-Akt pathway. Biochem Biophys Res Commun. 2007; 355: 611-618.
62. Leu SJ, Chen N, Chen CC, et al. Targeted mutagenesis of the angiogenic protein CCN1 (CYR61). Selective inactivation of integrin alpha6beta1-heparan sulfate proteoglycan coreceptor-mediated cellular functions. J Biol Chem. 2004; 279: 44177-44187.
63. Nishida T, Kondo S, Maeda A, Kubota S, Lyons KM, Takigawa M., CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1alpha expression in a chondrocytic cell line, HCS-2/8, under hypoxic condition. Bone. 2009; 44: 24-31.
64. Fontana L, Chen Y, Prijatelj P, et al. Fibronectin is required for integrin alphavbeta6-mediated activation of latent TGF-beta complexes containing LTBP-1. Faseb J. 2005; 19: 1798-1808.
65. Hamidouche Z, Fromigue O, Ringe J, et al. Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis. Proc Natl Acad Sci U S A. 2009; 106: 18587-18591.
66. Gao R, Brigstock DR., Low density lipoprotein receptor-related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. Hepatol Res. 2003; 27: 214-220.
67. Segarini PR, Nesbitt JE, Li D, Hays LG, Yates JR 3rd, Carmichael DF., The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem. 2001; 276: 40659-40667.
68. Williams BO, Insogna KL., Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res. 2009; 24: 171-178.
69. Avsian-Kretchmer O, Hsueh AJ., Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol Endocrinol. 2004; 18: 1-12.
70. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007; 22: 19-28.
71. Winkler DG, Yu C, Geoghegan JC, et al. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem. 2004; 279: 36293-36298.
72. Winkler DG, Sutherland MS, Ojala E, et al. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem. 2005; 280: 2498-2502.
73. Hurvitz JR, Suwairi WM, Van Hul W, et al. Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. Nat Genet. 1999; 23: 94-98.
74. Urano T, Narusawa K, Shiraki M, et al. Association of a single nucleotide polymorphism in the WISP1 gene with spinal osteoarthritis in postmenopausal Japanese women. J Bone Miner Metab. 2007; 25: 253-258. (Pubitemid 47012483)
75. Wang SX, Laverty S, Dumitriu M, Plaas A, Grynpas MD., The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. Arthritis Rheum. 2007; 56: 1537-1548.
76. Lavigne P, Benderdour M, Lajeunesse D, et al. Subchondral and trabecular bone metabolism regulation in canine experimental knee osteoarthritis. Osteoarthritis Cartilage. 2005; 13: 310-317.
77. Koh JT, Zhao Z, Wang Z, Lewis IS, Krebsbach PH, Franceschi RT., Combinatorial gene therapy with BMP2/7 enhances cranial bone regeneration. J Dent Res. 2008; 87: 845-849.
78. Kwong FN, Harris MB., Recent developments in the biology of fracture repair. J Am Acad Orthop Surg. 2008; 16: 619-625.
79. Morgan EF, Mason ZD, Bishop G, et al. Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1-34) in metaphyseal bone healing. Bone. 2008; 43: 1031-1038.